| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Department of Biology, American University of Beirut, Beirut, Lebanon; Departments of 2 Pathology, 3 Neuropathology, 4 Biochemistry, 5 Biometrics, and 6 General Surgery of the Otto-von-Guericke University, Magdeburg, Germany; 7 Department of Medicine 1, University Hospital Erlangen, Erlangen, Germany; 8 CEPE-CNRS and 9 INSERM U682, Strasbourg, France; and 10 Department of Neuropathology, Friedrich-Schiller University Jena, Jena, Germany
Requests for reprints: Regine Schneider-Stock, Department of Pathology, Otto-von-Guericke University of Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany. Phone: 49-391-6715060; Fax: 49-391-6717839; E-mail: Regine.Schneider-Stock{at}med.ovgu.de.
Key Words: p53 CHEK1 apoptosis thymoquinone DNA damage
There are few reports describing the role of p53-dependent gene repression in apoptotic cell death. To identify such apoptosis-associated p53 target genes, we used the pro-oxidant plant-derived drug thymoquinone and compared p53+/+ and p53–/– colon cancer cells HCT116. The p53 wild-type (wt) status correlated with more pronounced DNA damage and higher apoptosis after thymoquinone treatment. A significant up-regulation of the survival gene CHEK1 was observed in p53–/– cells in response to thymoquinone due to the lack of transcriptional repression of p53. In p53–/– cells, transfection with p53-wt vector and CHEK1 small interfering RNA treatment decreased CHEK1 mRNA and protein levels and restored apoptosis to the levels of the p53+/+ cells. p53–/– cells transplanted to nude mice treated with thymoquinone up-regulated CHEK1 expression and did not undergo apoptosis unlike p53+/+ cells. Immunofluorescence analysis revealed that the apoptosis resistance in p53–/– cells after thymoquinone treatment might be conveyed by shuttling of CHEK1 into the nucleus. We confirmed the in vivo existence of this CHEK1/p53 link in human colorectal cancer, showing that tumors lacking p53 had higher levels of CHEK1, which was accompanied by poorer apoptosis. CHEK1 overexpression was correlated with advanced tumor stages (P = 0.03), proximal tumor localization (P = 0.02), and worse prognosis (1.9-fold risk, univariate Cox regression; Kaplan-Meier, P = 0.04). We suggest that the inhibition of the stress response sensor CHEK1 might contribute to the antineoplastic activity of specific DNA-damaging drugs. [Cancer Res 2008;68(14):5609–18]
This article has been cited by other articles:
![]() |
S. Banerjee, A. O. Kaseb, Z. Wang, D. Kong, M. Mohammad, S. Padhye, F. H. Sarkar, and R. M. Mohammad Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic Cancer Cancer Res., July 1, 2009; 69(13): 5575 - 5583. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |